You just read:

Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19

News provided by

Roivant Sciences

18 Mar, 2020, 20:30 GMT